Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06538961 · ClinicalTrials.gov registry record
Immune Registry for BK in Kidney Transplant Recipients
A clinical trial of Kidney Transplant; Complications and BK Virus Infection, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT06538961 is a study of Kidney Transplant; Complications and BK Virus Infection that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 60 participants, below the 119-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06538961, a study of Kidney Transplant; Complications and BK Virus Infection, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Kidney transplantation (KT) is the best treatment modality available to date for patients with advanced kidney disease and the success of KT is dependent on maintaining a selective intricate balance between the risk of rejection and infections in KT recipients. BK virus is an important clinical infection affecting the post-transplant outcomes in KT recipients. BK nephropathy can affect 8-15% of patients after KT causing acute kidney injury, increased risk of rejection and fibrosis leading to additional hospital stays, increasing overall health care cost burden, and in some cases graft loss. The exact pathogenesis and treatment options for BK nephropathy are not clearly understood. It is debatable whether BK nephropathy is a full fledge donor-derived infection or reactivation of the recipient's latent infection. Irrespective of etiology, the common consensus is that treatment of BK virus infection depends on the selective restoration of host immune responses and balancing the risk of rejection vs worsening of infection.
Conditions Studied
Interventions
- OTHER Blood samples: Main Study group
- OTHER Data Collection
- OTHER Urine Sample- Main Study group
- OTHER Urine sample- Sub-study group
- OTHER Blood sample: Sub-study group
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-05-29 |
| Est. Completion | 2026-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06538961
The ClinicalTrials.gov registry entry for NCT06538961 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (50% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Transplant; Complications appearing as the primary indexed condition, and to 5 interventions - of which Blood samples: Main Study group is the first listed.
NCT06538961 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06538961 about?
NCT06538961 is a clinical study titled "Immune Registry for BK in Kidney Transplant Recipients". Kidney transplantation (KT) is the best treatment modality available to date for patients with advanced kidney disease and the success of KT is dependent on maintaining a selective intricate balance between the risk of rejection and infections in KT recipients. BK virus is an important clinical infe...
What is the current status of trial NCT06538961?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2024-05-29. Estimated completion is 2026-05.
What conditions does trial NCT06538961 study?
This clinical trial studies the following conditions: Kidney Transplant; Complications, BK Virus Infection.
What interventions are being tested in trial NCT06538961?
The interventions under investigation include: Blood samples: Main Study group (OTHER), Data Collection (OTHER), Urine Sample- Main Study group (OTHER), Urine sample- Sub-study group (OTHER), Blood sample: Sub-study group (OTHER).
Who is sponsoring clinical trial NCT06538961?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06538961 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant; Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program
RECRUITING · NA
-
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
RECRUITING · Phase 2
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
-
Double Voiding and Post-transplant UTI
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.